Get SEC filing alerts via email and in your feed for VIVOS INC
RDGL
VIVOS INC
About VIVOS INC
Vivos Inc. develops precision radionuclide therapy devices, primarily RadioGel, for treating non-resectable tumors in humans and animals. Its core focus includes FDA-approved cancer treatments, veterinary oncology solutions under the IsoPet brand, and innovative isotope technologies. The company leverages strategic partnerships, proprietary patents, and clinical trials to deliver targeted, minimally invasive therapies with competitive advantages in safety, efficacy, and regulatory progress.
This description was generated via AI from an annual report.
Updated 9 months ago.